Joint modeling of survival and longitudinal non-survival data: Current methods and issues. Report of the DIA Bayesian joint modeling working group

Statistics in Medicine

Volumn 34, Issue 14, 2015, Pages 2181-2195

  Lawrence Gould, A ^a   Boye, Mark Ernest ^b   Crowther, Michael J ^c   Ibrahim, Joseph G ^d   Quartey, George ^e   Micallef, Sandrine ^f   Bois, Frederic Y ^g,h  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d The University of North Carolina at Chapel Hill   (United States)

^e GENENTECH INC   (United States)

^f SANOFI   (France)

^g UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^h INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Applications; Random effects; Software; Time dependent

Indexed keywords

CANCER VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHARMACOLOGICAL BIOMARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BAYES THEOREM; COMPUTER PREDICTION; COMPUTER PROGRAM; DATA ANALYSIS; GRAFT FAILURE; HUMAN; INTERSTITIAL LUNG DISEASE; JOINT MODELING; KIDNEY GRAFT; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PATIENT RISK; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RANDOM EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS; SURVIVAL; TIME DEPENDENT SLOPE; ADVERSE EFFECTS; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); DRUG DESIGN; EPIDEMIOLOGY; GRAFT REJECTION; HIV INFECTIONS; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; SOFTWARE; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; BAYES THEOREM; BIOMARKERS, PHARMACOLOGICAL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; EPIDEMIOLOGIC RESEARCH DESIGN; GRAFT REJECTION; HIV INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; SOFTWARE; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84930151542     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6141     Document Type: Article

References (75)

1. Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. Journal of Clinical Oncology 2010; 28:2796-2801.
2. McArdle JJ, Small BJ, Bäckman L, Fratiglioni L. Longitudinal models of growth and survival applied to the early detection of Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 2005; 18:234-241.
3. Hatfield LA, Boye ME, Carlin BP. Joint modeling of multiple longitudinal patient-reported outcomes and survival. Journal of Biopharmaceutical Statistics 2011; 21:971-981.
4. Hatfield LA, Boye ME, Hackshaw MD, Carlin BP. Multilevel Bayesian models for survival times and longitudinal patient-reported outcomes with many zeros. Journal of the American Statistical Association 2012; 107:875-885.
5. Wang P, Shen W, Boye ME. Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial. Health Services & Outcomes Research Methodologies 2012; 12:182-199.
6. Basch E. Toward patient-centered drug development in oncology. New England Journal of Medicine 2013; 369:397-400.
7. Chen LM, Ibrahim JG, Chu HT. Sample size and power determination in joint modeling of longitudinal and survival data. Statistics in Medicine 2011; 30:2295-2309.
8. Bottomley A, Vanvoorden V, Flechtner H, Therasse P. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. European Journal of Cancer 2003; 39:275-285.
9. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998; 317:1191-1194.
10. Testa M, Simonson D. Assessment of quality-of-life outcomes. New England Journal of Medicine 1996; 334:835-840.
11. EMEA. Guideline on the evaluation of anticancer medicinal products in man, EMEA, 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf.Accessed8-27-2013.
12. Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics, Food and Drug Administration, 2007. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.Accessed8-27-2013.
13. Food and Drug Administration. Guidance for industry: patient-reported outcomes measures: use in medical product development to support labeling claims, Food and Drug Administration, 2009. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed8-27-2013.
14. Basch E. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value in Health 2012; 15:401-403.
15. Calvert M. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. Journal of the American Medical Association 2013; 309:814-822.
16. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Chapman and Hall/CRC: Boca Raton, FL, 2010.
17. Frees EW. Assessing cross-sectional correlation in panel data. Journal of Econometrics 1995; 69:393-414.
18. Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica 2004; 14:809-834.
19. Huang X, Stefanski LA, Davidson M. Latent-model robustness in joint models for a primary endpoint and a longitudinal process. Biometrics 2009; 65:719-727.
20. Rizopoulos D, Verbeke G, Molenberghs G. Shared parameter models under random effects misspecification. Biometrika 2008; 95:63-74.
21. Crowther MJ, Abrams KR, Lambert PC. Flexible parametric joint modelling of longitudinal and survival data. Statistics in Medicine 2012; 31:4456-4471.
22. Kim S, Zeng D, Chambless L, Li Y. Joint models of longitudinal data and recurrent events with informative terminal event. Statistics in Biosciences 2012; 4:d62-281.
23. Liu L, Huang X. Joint analysis of correlated repeated measures and recurrent event processes in the presence of death, with application to a study on acquired immune deficinecy syndrome. Journal of the Royal Statistical Society Series C 2009; 58:65-81.
24. Zeng D, Lim DY. Semiparametric transformation models with random effects for joint analysis of recurrent and terminal events. Biometrics 2009; 65:746-752.
25. Postel-Vinay S, Gomez-Roca C. Molife LRea. Phase 1 trials of molecularly targeted agents: should we pay more attention to late toxicities. Journal of Clinical Oncology 2011; 29:1728-1735.
26. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 2005; 61:344-354.
27. Di Scala L, Pylvanianen I, Molloy B, Manlius C, Vittori L, Sahmoud T, Lebwohl D, Zuber EP. A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 2008; 26:S1130 (Abstract).
28. Kathman SJ, Williams DH, Hodge JP, Dar M. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemothearpy and Pharmacology 2009; 63:469-476.
29. Ozawa K, Minami H, Sato H. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients. Cancer Science 2007; 98:1985-1992.
30. Gillespie WR. Computational tools for Bayesian PKPD modeling, Metrum Institute, 2010. Available from: http://legacy.samsi.info/201011/pkpd/gillespiePKPDSoftwareSAMSI2010.pdf [Accessed on 7 March 2014].
31. Lunn DJ. BUGS/WBDiff software: Bayesian inference for dynamical systems, MRC Biostatistics Unit, Cambridge University, 2011. Available from: http://sbml.org/images/2/2f/StatMeeting_Lunn.pdf [Accessed on 7 March 2014].
32. Bois FY. GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models. Bioinformatics 2009; 25:1453-1454.
33. Bauer RJ, Ludden T. MCMC Bayesian analysis for population analysis of complex pK/pD models in NonMEM VII beta. Clinical Pharmacology and Therapeutics 2009; 85:S30-S31.
34. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS Journal 2007; 9:E60-E83.
35. Gastonguay MR, French JL, Heitjan DF, Rogers JA, Ahn JE, Ravva P. Missing data in model-based pharmacometric applications: points to consider. Journal of Clinical Pharmacology 2010; 50:63S-74S.
36. Rizopoulos D, Ghosh P. A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event. Statistics in Medicine 2011; 30:1366-1380.
37. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society Series B-Statistical Methodology 1972; 34:187-220.
38. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1:465-480.
39. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics 1997; 53:330-339.
40. Hsieh F, Tseng YK, Wang JL. Joint modeling of survival and longitudinal data: likelihood approach revisited. Biometrics 2006; 62:1037-1043.
41. Huang YX, Dagne G, Wu L. Bayesian inference on joint models of HIV dynamics for time-to-event and longitudinal data with skewness and covariate measurement errors. Statistics in Medicine 2011; 30:2930-2946.
42. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of teratment effects. Statistics in Medicine 2002; 21:2175-2197.
43. Cox DR, Oakes D. Analysis of Survival Data. Chapman & Hall Ltd: London, 1984.
44. Ye W, Lin X, Taylor JMG. Semiparametric modeling of longitudinal measurements and time-to-event data - a two-stage regression calibration approach. Biometrics 2008; 64:1238-1246.
45. Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy - the CASCADE collaboration: a collaboration of 23 cohort studies. PLOS medicine 2010; 7(2)e1000239:1-13.
46. Tsiatis AA, DeGruttola V, Wulfsohn MS. Modeling the relationship of survival to longitudinal data measured with error: applications to survival and CD4 counts in patients with AIDS. Journal of the American Statistical Association 1995; 90:27-37.
47. Faucett CJ, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. Statistics in Medicine 1996; 15:1663-1685.
48. Ibrahim JG, Chen MH, Sinha D. Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine studies. Statistica Sinica 2004; 14:863-883.
49. Wang Y, Taylor JMG. 'Jointly modelling longitudinal and event time data with application to AIDS studies', 2000. (unpublished ms).
50. Taylor JMG, Cumberland WG, Sy JP. A stochastic model for analysis of longitudinal AIDS data. Journal of the American Statistical Association 1994; 89:727-736.
51. Sweeting MJ, Thompson SG. Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture. Biometrical Journal 2011; 53:750-763.
52. Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. Journal of Statistical Software 2010; 35:1-33.
53. Philipson P, Sousa I, Diggle PJ. joineR - joint modelling of repeated measurements and time-to-event data, 2013. Available from: http://cran.r-project.org/ [Accessed on 7 March 2014].
54. Lunn DJ, Thomas A, Best N, Spiegelhalter DJ. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10:325-337.
55. Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. American Statistician 2004; 58:16-24.
56. Rizopoulos D. JMbayesL joint modeling of longitudinal and time-to-event data under a Bayesian approach, 2013. Available from: http://cran.r-project.org/web/packages/JMbayes/index.html [Accessed on 7 March 2014].
57. Zhang D, Chen MH, Ibrahim JG, Boye ME, Shen W. JMFit: a SAS macro for assessing model fit in joint models of longitudinal and survival data, 2013. (Submitted for publication to Journal of Statistical Software).
58. Crowther MJ, Abrams KR, Lambert PC. Joint modeling of longitudinal and survival data. The STATA Journal 2013; 13:165-184.
59. Hoover DR, Graham NMG, Chen B, Taylor JMG, Phair J, Zhou SYJ, Munoz A. Effect of CD4+ cell count measurement variability on staging HIV-1 infection. Journal of Acquired Immune Deficiency Syndrome 1992; 5:794-802.
60. Lange N, Carlin BP, Gelfand AE. Hierarchical Bayes models for the progression of HIV infection using longitudinal CD4 T-cell numbers (Disc. p 626-632). Journal of the American Statistical Association 1992; 87:615-626.
61. Taylor JMG, Fahey J, Detels R, Giorgi J. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. Journal of Acquired Immune Deficiency Syndrome 1989; 2:114-124.
62. DeGruttola V, Wulfsohn MS, Fischl M, et al. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1993; 6:359-365.
63. DeGruttola V, Tu XM. Modeling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics 1994; 50:1003-1014.
64. Lavalley MP, DeGruttola V. Models for empirical Bayes estimators of longitudinal CD4 counts. Statistics in Medicine 1996; 15:2289-2305.
65. Tsiatis AA, Dafni U, DeGruttola V, Propert KJ, Strawderman RL, Wulfsohn MS. The relationship of CD4 counts over time to survival in patients with AIDS: is CD4 a good surrogate marker? In AIDS Epidemiology: Methodological Issues. Birkhauser: Boston, 1992; 256-274.
66. Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, Lennox JL, Dube MP, MacGregor RR, Currier JS. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. Journal of Infectious Diseases 2003; 187:1046-1052.
67. Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double blind, placebo-controlled trial (ACTG Protocol 362). Annals of Internal Medicine 2000; 133:493-503.
68. Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, Polsky B. Cytomegaloviris (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS clinical trials group protocol 360). Clinical Infectious Diseases 2003; 37:567-578.
69. Hardy W, Feinberg J, Finkelstein D, Power M, He W, Kaczka C, Frame P, Holmes M, Wasking H, Fass R, Powderly W, Steigbigel R, Zuger A, Holzman R. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. New England Journal of Medicine 1992; 327:1842-1848.
70. Havlir D, Dube M, Sattler F. Prophylaxis against disseminated mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. New England Journal of Medicine 1996; 335:392-398.
71. Nightingale S, Cameron D, Gordin F, Sullam P, Cohn D, Chaisson R, Eron L, Sparti P, Bihari B, Kaufman D, Stern J, Pearce D, Weinberg W, Lamarca A, Siegal FP. Two controlled trials of rifabutin prophylaxis against mycobacterium avium complex infection in AIDS. New England Journal of Medicine 1993; 329:828-833.
72. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, Skahan KJ, Johnson P, Hamill R, Bamberger D, Pappas P, Koletar SL, Squires K, Larsen RTC, Hyslop N, Lai KK, Schneider DCK, Saag M, Dismukes W. Treatment of histoplasmosis with fliconazole in patients with acquired immunodeficiency syndrome (ACTG 174). American Journal of Medicine 1997; 103:223-232.
73. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani F. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy (ACTG Protocol 379). HIV Clinical Trials 2013; 6:136-146.
74. Brown ER, Ibrahim JG. Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine studies. Biometrics 2003; 59:686-693.
75. Huang X, Li G, Elashoff RM, Pan J. A general joint model for longitudinal measurements and competing risks survival data with heterogeneous random effects. Lifetime Data Analysis 2011; 17:80-100.